LAVA Therapeutics NV Stock News
$1.29
0.39%
today
Nasdaq,
Feb 28, 09:47 pm CET
LAVA Therapeutics NV Stock News
Neutral
GlobeNewsWire
●
about 2 months ago
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody®, LAVA-12...
Neutral
GlobeNewsWire
●
3 months ago
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, reported financial results for the third quarter ended September 30, 2024 and announced a strategic pipeline reprio...
Neutral
GlobeNewsWire
●
6 months ago
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26th Annual ...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
